The Ophthalmology Times Group talked to an optometrist practice about their experience with ocular nutraceuticals
Ocuphire Pharma and Opus Genetics announce merger
The company also announced it will seek a strategic partner to continue development of APX3330, an oral small-molecule inhibitor of Ref-1 for the treatment of non-proliferative diabetic retinopathy.
PHOTON Results and Their Relation to DME Patients in Your Practice
John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.
Alzheimer disease retinopathy and brain-to-eye β-amyloid transport
The research findings highlighted a new therapeutic avenue in ocular and neurodegenerative disease
PULSAR Results and Their Relation to nAMD Patients in Your Practice
John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.
What's missing in patient education?
A different approach better serves patients with diabetic retinopathy
EU CHMP confirms negative opinion on marketing authorisation application of intravitreal pegcetacoplan from Apellis
The agency confirmed its June 2024 negative opinion after Apellis requested re-examination of the EMA's initial response